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An essential cytokine system for the osteoclast biology in multiple myeloma (MM) consists of the receptor of activator of NF-κB
ligand (RANKL), its receptor (RANK), and the soluble decoy receptor, osteoprotegerin (OPG). Myeloma cells cause imbalance
in OPG/RANKL interactions. We measured serum levels of OPG, soluble (s) RANKL, sRANKL/OPG ratio, markers of disease
activity [LDH, CRP, interleukin-6 (IL-6), β2-microglobulin (B2M)], and angiogenic factors [hepatocyte growth factor (HGF),
vascular endothelial growth factor (VEGF)], in 54 newly diagnosed MM patients and in 25 of them in plateau phase. All the above
values were higher in MM patients compared to controls and decreased in plateau phase. sRANKL and RANKL/OPG were higher
with advancing disease stage and skeletal grade. Signiﬁcant correlations were found among RANKL and RANKL/OPG with HGF,
LDH, VEGF, IL-6, and B2M. In conclusion, RANKL and OPG play signiﬁcant roles in MM pathophysiology, as regulators of bone
turnover and mediators of angiogenesis.
1.Introduction
Multiple myeloma is a malignant plasma cell proliferation
localized in the bone marrow with debilitating skeletal
involvement. Much of its morbidity is accounted to bone
pain and pathologic fractures due to the imbalance between
bone formation and breakdown in favor of the latter [1–4].
These complications are due to an excessive osteoclast
activity, which are stimulated by osteoclast-activating fac-
tors, including Tumor Necrosis Factor (TNF), Interleukin-
1 (IL-1), Interleukin-6 (IL-6), the chemokines Macrophage
Inﬂammatory Protein-1a (MIP-1a), Macrophage Inﬂamma-
tory Protein-1β (MIP-1β), and Stroma cell-Derived Factor-
1a (SDF-1a) [2, 5, 6].
However, an essential cytokine system for the osteoclast
biology has been identiﬁed and consists of the receptor of
activator of NF-κB ligand (RANKL), its receptor RANK,
and the soluble decoy receptor, osteoprotegerin (OPG) [7–
9]. The RANKL has been identiﬁed and associated with
the enhancement in osteoblast-induced bone resorption,
while OPG blocks RANKL and inhibits bone resorption
[8, 10]. Myeloma plasma cells have been found to induce
an imbalance in the OPG/RANKL interactions, increasing
RANKL expression and decreasing OPG availability in the
bone microenvironment, inducing an enhancement of the
osteoclastic activation and increased bone resorption [8, 11].
RANKL stimulates osteoclast diﬀerentiation and activity
and also inhibits osteoclast apoptosis. RANKL is mainly
produced by osteoblastic lineage cells, immune cells, and
some malignant cells [12].
Osteoprotegerin is a Tumor Necrosis Factor Receptor-
2 (TNFR-2) and CD40 homologous protein, which lacks a
transmembrane domain and is secreted into the extracellular
space as a homodimeric glycoprotein [13, 14]. OPG was
found in serum of peripheral blood in various forms, in
complexes with soluble RANKL and a free non-bound
portion. The heterogeneity of these circulating forms may
account for the discrepancies for absolute values reported in2 Mediators of Inﬂammation
the literature [11]. Based on the heterogeneity of circulating
forms and other technical aspects, the protein used as
standardandthesuitablecalibratordiluentcouldaccountfor
discrepantresultsthathavebeenobtainedbydiﬀerentgroups
in the literature [11, 15].
Bone marrow angiogenesis is an important additional
process contributing to disease progress [16, 17]. Various
angiogenic cytokines, such as vascular endothelial growth
factor (VEGF) and hepatocyte growth factor (HGF) increase
myeloma cell proliferation and accelerate bone resorption
[16, 18].
The purpose of this study was to evaluate serum levels of
OPG, soluble RANKL (sRANKL), the ratio sRANKL/OPG,
VEGF, HGF, and known factors of disease activity at
diagnosis and in plateau phase and to estimate the eﬀect of
treatment on their circulating levels in patients with MM.
2. Patientsand Methods
2.1. Patients. Fifty-four MM patients (28 males, 26 females)
were included in this study. The median age was 64 years
(range51–87years).Patientswerediagnosedandcategorized
according to the Durie-Salmon classiﬁcation system [19].
Sixteen patients were classiﬁed as stage I, 19 as stage II,
and 19 as stage III. The types of monoclonal protein were
21 IgGκ,8I g G λ,7I g A κ,1 1I g A λ, and light chain disease
for 7 patients. Bone involvement was graded according to
standard X-ray evaluation into two scores: low score in
26 patients overall, including patients with no lesions, one
bone involved, or diﬀuse osteoporosis; and high score in
28 patients overall, including patients with lesions in more
than one bone or presence of bone fracture. None of the
patients had received any treatment with corticosteroids or
biphosphonates before entering the study. Eighteen patients
had normal radiographic ﬁndings of the skeleton, the rest
displayed osteolytic lesions. Twenty-ﬁve of the patients
achieved complete remission or very good partial remis-
sion after treatment with PAD (bortezomib, doxorubicin,
dexamethasone) regimen followed by autologous stem cell
transplantation and considered to be in plateau phase.
Twenty age- and sex-matched healthy subjects (12 male and
8 female, mean age 63.6 ± 10.8 years) were recruited as
controls among blood donors (up to 60 years of age) and
people following a physical training program (over 60 years
ofage).Informedconsentforthestudywasobtainedfromall
subjects. The study was conducted with the understanding
and the consent of the human subject. The responsible
Ethical Committee has approved the experiments.
2.2. Methods. Serum samples from patients were collected
before starting treatment at diagnosis and during stable
disease. Sera collected from patients and controls were
aliquoted into separate vials and stored at −7◦C. All assays
were performed at the end of the study, in order to avoid
interassay variability.
ThedetectionofVEGF,HGF,IL-6,sRANKL,andOPGin
the serum was performed by a solid-phase sandwich ELISA,
using monoclonal antibodies against VEGF, HGF, and IL-
6 (Quantikine, R&D systems Inc. Mineapolis, MN, USA)
Table 1: Serum concentrations of measured parameters in healthy
controls and patients with multiple myeloma.
n Mean ± SD P (Mann Whitney)
OPG pmol/L
Control 20 6.4 ±5.3 < 0.03
Patients 54 12.5 ±11.5
RANKL pmol/L
Control 20 13.54 ±9.90 = 0.007
Patients 54 364.48 ±393.63
RANKL/OPG
Control 20 14.44 ±28.39 NS
Patients 54 51.69 ±70.77
HGF pg/mL
Control 20 465.3 ±163.4 < 0.001
Patients 54 1612.2 ±1107.5
LDH IU/L
Control 20 163.1 ±36.4 < 0.01
Patients 54 228.9 ±77.2
VEGF pg/mL
Control 20 90.2 ±14.4 < 0.001
Patients 54 272.3 ±178.7
B2M mg/dL
Control 20 1.5 ±0.6 < 0.001
Patients 54 3.9 ±3.8
CRP mg/L
Control 20 0.4 ±0.1 < 0.001
Patients 54 1.1 ±1.3
IL-6 pg/mL
Control 20 0.8 ±0.5 < 0.001
Patients 54 6.4 ±5.1
and sRANKL and OPG antibodies (Bio Vendor-Laboratorni
Medicina as Brno, Czech Republic). Measurements were
performed according to the manufacturers’ instructions.
Brieﬂy, antibodies speciﬁc for each growth factor (VEGF,
HGF, IL-6, sRANKL, and OPG) were coated in microtitter
wells. After the addition of controls and samples and a
ﬁrst incubation and washing, an enzyme-linked polyclonal
antibody speciﬁc for each growth factor was added to each
well. After an incubation time and the last washing step, the
remaining conjugate is allowed to react with the substrate.
During the next step, the reaction was stopped by addition
of speciﬁc solution, and the absorbance of the resulting
color is measured at 450nm. Biochemical markers that were
studied were C-reactive protein (CRP), β2-microglobulin
(B2M), and serum lactate dehydrogenase (LDH). The above
mentioned parameters were evaluated using conventional
techniques. CRP was determined by nephelometry, B2M by
radioimmunoassay, and serum LDH was determined using
standard laboratory methods. Radiographic examination
including skull, pelvis, long bones and cervical, thoracic, and
lumbar spine was carried out in all patients as a routine
staging procedure. Bone disease was graded according to
Durie and Salmon criteria [19].Mediators of Inﬂammation 3
Table 2: Mean ± SD values of the measured parameters in the
group of MM patients in diﬀerent disease stages.
Stage Mean ± SD P
OPG (pmol/L) 1 16.5 ±16.2N S
21 1 .1 ±9.2
31 0 .4 ±7.9
RANKL pmol/L 1 72.01 ±64.05 < 0.001
2 235.29 ±107.45
3 739.98 ±445.84
RANKL/OPG 17 .62 ±8.90 < 0.001
24 8 .63 ±84.75
39 1 .87 ±63.71
HGF (pg/mL) 1 804.3 ±294.9 < 0.001
2 1547 ±469.1
3 2356.8 ±1466.1
LDH (IU/L) 1 180.4 ±31.1 < 0.002
2 218.5 ±62.2
3 280.2 ±88.9
VEGF (pg/mL) 1 140.1 ±105.0 < 0.001
2 230.9 ±141.8
3 425.1 ±150.8
B2M (mg/dL) 1 2.1 ±0.9 < 0.001
24 .4 ±5.3
34 .8 ±3.2
CRP (mg/L) 1 1.5 ±2.1N S
20 .9 ±0.7
31 .1 ±0.6
IL-6 (pg/mL) 1 3.4 ±2.1 < 0.001
25 .8 ±2.7
39 .5 ±6.9
2.3. Statistical Analysis. Data are presented as means ± SD.
The Mann-Whitney U-test was applied to evaluate any
diﬀerence in serum cytokine levels in patients and healthy
individuals. Nonparametric tests were also used (Mann-
Whitney and Wilcoxon for independent and paired two
samplesstatistics).Theinvestigationofpotentialcorrelations
among variables was carried out with the Spearman’s rho
correlation coeﬃcient. P values < 0.05 were considered to
be statistically signiﬁcant.
3. Results
The laboratory ﬁndings studied in multiple myeloma
patients and in healthy controls are shown in Table 1.
Serum mean concentration of OPG was 12.5 ± 11.5 (0.7–
60.2)pmol/L in multiple myeloma patients and 6.4 ± 5.3
(0.7–17.4) pmol/L in healthy subjects (P<0.03) (by Mann-
Whitney test) (Figure 1). The mean concentrations of OPG
in stages I and II of the disease were higher than in stage
III, without statistical signiﬁcance. Our results also showed
that OPG serum levels were signiﬁcantly decreasing after
treatment (11.5 ± 10.9v e r s u s1 3 .3 ± 14.0pmol/L,P<0.03,
Wilcoxon test) (Figure 2). Serum concentrations of sRANKL
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Figure 1: Serum OPG concentrations in MM patients and healthy
controls.
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Figure 2: Serum OPG concentrations before and after treatment.
werealsoincreasedinpatientscomparedtocontrols,whereas
sRANKL/OPG ratio did not show signiﬁcant diﬀerence.
On the other hand, both serum levels of sRANKL and
sRANKL/OPG ratio were increased with disease progression
and decreased after eﬀective treatment.
In healthy individuals, mean serum levels for HGF were
465.3 ± 163.4 (311.9–898.7)pg/mL, for VEGF 90.2 ± 14.4
(68.7–111.6)pg/mL and for IL-6 0.8 ± 0.5 (0.4–2.0)pg/mL.
Pretreatment VEGF, HGF, and IL-6 serum levels were
increased in MM patients in comparison with healthy
individuals (P<0.001, in all cases). Signiﬁcant diﬀerences
were found for HGF, VEGF, and IL-6 between the stages of
the disease (Table 2).
3.1. Relationship between Biochemical Markers, Cytokines,
and Skeletal Involvement. There was a positive correlation
between increasing bone lesion score and serum median
concentrations of sRANKL (P<0.001), sRANKL/OPG ratio
(P<0.001), VEGF (P<0.001) (Figure 3), HGF (P<0.004),4 Mediators of Inﬂammation
Table 3: Mean ± SD values of the measured parameters in the group of MM patients according to the skeletal involvement.
Bone involvement Mean ± SD P
OPG (pmol/L) Low Score (Grade 0-1) 13.8 ±13.6N S
H i g hS c o r e( G r a d e2 - 3 ) 1 1 .3 ±9.3
RANKL pmol/L Low Score (Grade 0-1) 103.08 ±79.29 < 0.001
High Score (Grade 2-3) 589.84 ±417.48
RANKL/OPG Low Score (Grade 0-1) 14.66 ±21.97 < 0.001
H i g hS c o r e( G r a d e2 - 3 ) 8 3 .61 ±82.39
HGF (pg/mL) Low Score (Grade 0-1) 1150.4 ±535.9 < 0.004
High Score (Grade 2-3) 2010.2 ±1312.0
LDH (IU/L) Low Score (Grade 0-1) 209.9 ±74.70 . 0 5
High Score (Grade 2-3) 245.3 ±76.8
VEGF (pg/mL) Low Score (Grade 0-1) 170.7 ±115.1 < 0.001
High Score (Grade 2-3) 359.9 ±178.7
B2M (mg/dL) Low Score (Grade 0-1) 2.9 ±2.7 < 0.04
H i g hS c o r e( G r a d e2 - 3 ) 4 .7 ±4.5
CRP (mg/L) Low Score (Grade 0-1) 1.3 ±1.7N S
H i g hS c o r e( G r a d e2 - 3 ) 1 .0 ±0.7
IL-6 (pg/mL) Low Score (Grade 0-1) 4.7 ±4.9 < 0.001
H i g hS c o r e( G r a d e2 - 3 ) 7 .8 ±4.9
Table 4: Correlation among RANKL and RANKL/OPG ratio with markers of angiogenesis and disease activity (NS: not signiﬁcant).
OPG HGF LDH VEGF B2M CRP IL-6
RANKL r NS 0.529 0.344 0.707 0.401 NS 0.422
P NS < 0.0001 < 0.01 < 0.0001 < 0.003 NS < 0.001
RANKL/OPG r −0.548 0.612 0.352 0.637 0.362 NS 0.390
P< 0.0001 < 0.0001 < 0.009 < 0.0001 < 0.007 NS < 0.004
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Figure 3: Serum VEGF levels according to bone involvement score.
IL-6 (P<0.001), LDH (P<0.05), and B2M (P<0.04),
while OPG levels according to bone disease were higher in
low score (grade 0-1) in comparison to high score (grade 2-
3) but without statistical signiﬁcance (Table 3).
3.2. Correlation between Measured Parameters. Positive cor-
relations were found between sRANKL with HGF, VEGF,
LDH, VEGF, B2M, and IL-6, whereas more powerful corre-
lations were found between sRANKL/OPG ratio with OPG
and the above parameters (Table 4). Serum HGF correlated
positively with LDH (r = 0.38, P<0.002), VEGF (r =
0.59, P<0.0001), B2M (r = 49, P<0.0001), CRP (r =
420, P<0.001), and IL-6( r = 61, P<0.0001).
No correlation between the angiogenic cytokines VEGF,
HGF and IL-6, and the serum OPG levels was found.
Similarly, no correlation between the parameters of disease
activity CRP, B2M, and LDH serum levels with OPG levels
was found.
Finally, statistically signiﬁcant diﬀerences were observed
intheserumlevels,beforeandaftertreatment,ofOPG,HGF,
LDH, VEGF, and IL-6 (Table 5).
4. Discussion
Angiogenesis is a crucial factor for the growth and progres-
sion of multiple myeloma [16, 20, 21]. Various angiogenicMediators of Inﬂammation 5
Table 5: Mean ± SD values of the measured parameters in MM patients before and after treatment.
Mean ± SD P (Wilcoxon test)
OPG (pmol/L) Before treatment 11.5 ±10.9 < 0.03
After treatment 13.3 ±14.0
RANKL (pmol/L) Before treatment 335.10 ±306.68 < 0.005
After treatment 99.95 ±108.52
RANKL/OPG Before treatment 76.55 ±96.25 < 0.01
After treatment 10.81 ±9.91
HGF (pg/mL) Before treatment 1433.0 ±1100.9 < 0.001
After treatment 765.9 ±210.5
LDH (IU/L) Before treatment 218.6 ±76.0 < 0.002
After treatment 176.1 ±33.4
VEGF (pg/mL) Before treatment 243.8 ±177.0 < 0.001
After treatment 120.7 ±40.4
IL-6 (pg/mL) Before treatment 3.5 ±3.6 < 0.003
After treatment 2.4 ±1.2
cytokines have been characterized as potent mitogens with
angiogenic activity [22, 23]. Neovascularization and bone
marrowmicroenvironmentcapacitytosupporttheprolifera-
tion of tumor cells as well as the interactions between plasma
cells and osteoclasts are important processes involved in MM
pathogenesis [24]. VEGF is a potent mitogen for endothelial
cells and is regarded as one of the most important molecules
for its role in the vascularization of bone tissues [25].
Another factor with potent angiogenic activity is the HGF.
HGF and its receptor c-met are expressed simultaneously
in myeloma cells [26]. In MM patients elevated levels of
HGF in the serum have been found to be associated with a
poor prognosis [16, 27]. HGF appears to play a signiﬁcant
role in tumor angiogenesis by stimulating endothelial cell
migration, proliferation, and capillary tube formation [28].
T h r e ep o t e n t i a ln o v e lr e g u l a t o r so fe n d o t h e l i a lc e l l
function and angiogenesis have been described. These are
OPG and its ligands, RANKL and TNF-Related Apoptosis
Inducing Ligand (TRAIL) [29] .I nar e c e n ts t u d y ,i th a s
been found that OPG is expressed in neovessels associated
with malignant tumors and in angiogenic microvessels
associated with inﬂammatory osteodestructive diseases [29–
31]. Moreover, OPG with other angiogenic factors such as
VEGF was found to have an additive eﬀect on endothelial
cell tube formation [32]. Since OPG is a decoy receptor
for the above TNF family ligands, it seems that it exerts
its angiogenic eﬀect through inhibition of one or both of
these molecules. In fact, using excess molar amounts of
either TRAIL or RANKL, the angiogenic activity of OPG
can be blocked. However, only RANKL was found to be
an angiogenesis inhibitor by its own. So, RANKL reduces
endothelial cell proliferation and induces their apoptosis, in
vitro[13], whereasits role in regulating cell proliferation and
survivaldiﬀersbetweencelltypes,mainlyduetothecomplex
network of signals initiated by its interaction with RANK.
IL-6 has been proposed as the major myeloma plasma cell
growth factor. Furthermore, IL-6 has been shown to be
a potent bone resorbing factor and may be involved in the
production of bone lesions in MM patients [33].
In the present study, our results showed increasing serum
levelsofOPGinMMpatientscomparedtothecontrolgroup
(P<0.01). OPG serum levels show a tendency to decrease
in advanced clinical stage and in patients with high score of
bone disease (the lowest OPG serum levels were observed
in patients with grade 3 bone disease). Higher levels of
OPG were found in early clinical stages and in patients with
minimalbonelesions(gradeI).Probably,inpatientswithout
bone involvement, activity of ostepblasts is still coupled
to the osteoclastic function. Osteoblast function decreases
as the disease evolves and is the result of the suppressive
eﬀects of MM cells [34]. Our results are in agreement with
others [11, 34] that OPG serum levels are elevated even in
myeloma patients without bone lesions. In later stages of the
disease,boneformationandosteoblastfunctionareimpaired
which gives an explanation to the reduced OPG levels in
patients with increased bone destruction [11, 34, 35]. No
statistically signiﬁcant diﬀerence was observed between OPG
serum levels in pre and posttreatment MM patients and no
signiﬁcantcorrelationwasobservedwithotherparametersof
diseaseactivityatdiagnosisandaftertreatmentsuchasLDH,
CRP, B2M, and IL-6. Recently, it has been reported that OPG
blocksbonecancer-inducedskeletaldestructionafteradmin-
istration experimentally in mice with sarcoma-induced oste-
olysis [36]. Probably as reported recently the decreased level
of OPG in myeloma bone disease gives a rationale for OPG
as a new treatment for MM bone disease [37].
Furthermore, in our study we have shown that serum
sRANKL levels were increased in MM patients compared
to controls. This agrees with most other studies [34, 38].
RANKL and RANKL/OPG ratios, signiﬁcantly increase with
advancing disease stage and in patients with severe bone
lesions. Furthermore, RANKL and RANKL/OPG ratios have
positive correlations with clinical stage, grade of bone
disease, angiogenic cytokines (HGF and VEGF), and factors6 Mediators of Inﬂammation
ofdiseaseactivitysuchasIL-6,B2M,andLDH.Theonlycor-
relation of OPG serum levels was with RANKL/OPG ratio.
To our best knowledge, no study until now has assessed
a correlation between OPG, RANKL serum levels, their ratio
RANKL/OPG and angiogenic cytokines such as HGF, VEGF,
and IL-6 serum levels. In conclusion, OPG and RANKL are
cytokines with a signiﬁcant role in the pathophysiology of
MM as regulators of bone turnover but also as signiﬁcant
mediators of angiogenesis. The exact role of OPG and
RANKL in the mechanisms of angiogenesis and osteo-
destructive disease in MM remains to be clariﬁed.
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